Given the fact that dietary zinc has been approved for the treatment of a number of diseases, and the safety profile of this drug is well known [15,16], we hope to move ahead with a formal clinical trial in patients with a subset of GNAO1 mutations, following the doses approved for the treatment of the pediatric Wilson disease [15]. Here, GNAO1 is linked to Wilson disease.